Financial, market and economic news

Novartis Gets Rights For Potential Acute Respiratory Distress Syndrome Cell Therapy

(RTTNews) – Novartis (NVS) said that it reached an exclusive worldwide license and collaboration agreement with Mesoblast (MESO) to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome or ARDS, including that associated with COVID-19.

Novartis said it will make a $25 million upfront…

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy